A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.

@article{Jackson2001AMO,
  title={A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.},
  author={Graham Hunter Jackson and P L Taylor and Graeme Murray Smith and Robert Marcus and A P Smith and Patricia Chu and Timothy James Littlewood and Andrew Duncombe and Michael Hutchinson and Atul B. Mehta and Steve A. Johnson and Patrick H. Carey and Michael J Mackie and P. S. Ganly and Gwendolyn E. Turner and Molly R Deane and Steve A. Schey and Jocelyn Brookes and Sall Tollerfield and Merne P Wilson},
  journal={British journal of haematology},
  year={2001},
  volume={112 1},
  pages={127-37}
}
The primary objective of this study was to determine the complete remission (CR) rate achieved with the FLAG (fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor) regimen in patients with relapsed or refractory acute myeloid leukaemia (AML) or de novo refractory anaemia with excess of blasts in transformation (RAEB-t). Secondary objectives were to evaluate survival and toxicity. Induction treatment consisted of between one and two courses of FLAG. Patients achieving CR… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Similar Papers

Loading similar papers…